LWP779
/ Shanghai Longwood Biopharmaceuticals
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 21, 2026
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LWP779 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=76 | Recruiting | Sponsor: Longwood Pharmaceuticals (Hangzhou) Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Cardiovascular • Ischemic stroke
1 to 1
Of
1
Go to page
1